Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics CFO Alan Musso named principal accounting officer after VP Finance exit

Neutral Impact 2 of 5 leadership Written later

Fulcrum Therapeutics said its vice president of finance and principal accounting officer, Greg Tourangeau, is leaving the company, with his tenure ending August 7, 2026. The board named Chief Financial Officer Alan Musso as principal accounting officer, effective the same date, so one executive now holds both the finance and accounting roles.

Key points

  • Greg Tourangeau's tenure as VP, Finance and principal accounting officer ends August 7, 2026, as previously disclosed in a June 11, 2026 8-K.
  • Board appointed Alan Musso, chief financial officer, as principal accounting officer on August 9, 2026, effective August 7, 2026.
  • Musso will receive no additional compensation for the added role.

The filing

CompanyFulcrum Therapeutics, Inc. (FULC)
Form8-K, current report
Filed with the SECAug 10, 2026, 8:43 AM ET
Accession number0001193125-26-341385

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.